TP53 and osteosarcoma: In this case, Chen et al. evaluated the clinical usefulness of alterations in p53, which also represent the most frequent driver mutation of osteosarcoma, being present in up to 90% of cases in a meta-analysis that included 210 patients with a mean age of 26 years and showed worse median survival in patients with p53 mutations [33].